{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:11:57Z","timestamp":1795032717327,"version":"4.10.2"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5R37CA215436-06"],"award-info":[{"award-number":["5R37CA215436-06"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5-P50-CA-228991-04"],"award-info":[{"award-number":["5-P50-CA-228991-04"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1U54CA283759-01"],"award-info":[{"award-number":["1U54CA283759-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1 R50CA283807-01A1"],"award-info":[{"award-number":["1 R50CA283807-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002956","name":"Foundation for Women's Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ovarian cancers (OVCAs) and endometrial cancers (EMCAs) with\n                    <jats:italic>CCNE1-<\/jats:italic>\n                    amplification are often resistant to standard treatment and represent an unmet clinical need. Synthetic-lethal screening identified loss of the CDK1 regulator, PKMYT1, as synthetically lethal with\n                    <jats:italic>CCNE1<\/jats:italic>\n                    -amplification. We hypothesize that\n                    <jats:italic>CCNE1<\/jats:italic>\n                    -amplification associated replication stress will be more effectively targeted by combining PKMYT1 inhibitor lunresertib (RP-6306), with ATR inhibitor camonsertib (RP-3500\/RG6526). Low dose combination RP-6306 with RP-3500 synergistically increases cytotoxicity more so in\n                    <jats:italic>CCNE1<\/jats:italic>\n                    -amplified compared to non-amplified cells. Combination treatment produces durable antitumor activity, reduces metastasis and increases survival in\n                    <jats:italic>CCNE1<\/jats:italic>\n                    -amplified patient-derived OVCA and EMCA xenografts. Mechanistically, low doses of RP-6306 with RP-3500 increase CDK1 activation more so than monotherapy, triggering rapid and robust induction of premature mitosis, DNA damage, and apoptosis in a\n                    <jats:italic>CCNE1<\/jats:italic>\n                    -dependent manner. These findings suggest that targeting CDK1 activity by combining RP-6306 with RP-3500 is an effective therapeutic approach to treat\n                    <jats:italic>CCNE1<\/jats:italic>\n                    -amplifed OVCAs and EMCAs.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-58183-w","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T13:59:36Z","timestamp":1743515976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7195-4897","authenticated-orcid":false,"given":"Haineng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Medvedev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arindam","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Kryczka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc L.","family":"Hyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Fourtounis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Stocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Aguado-Fraile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Petrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou Yun","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariya","family":"Shiwram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9975-8545","authenticated-orcid":false,"given":"Hyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1326-8981","authenticated-orcid":false,"given":"Roger A.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Gary","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0840-2368","authenticated-orcid":false,"given":"Fiona","family":"Simpkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"58183_CR1","first-page":"440","volume":"139","author":"AN Giaquinto","year":"2022","unstructured":"Giaquinto, A. N., Broaddus, R. R., Jemal, A. & Siegel, R. L. The changing landscape of gynecologic Cancer mortality in the United States. Obstet. Gynecol. 139, 440\u2013442 (2022).","journal-title":"Obstet. Gynecol."},{"key":"58183_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"58183_CR3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro, P. et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1\/GOG 3004 trial. J. Clin. Oncol. 41, 609\u2013617 (2023).","journal-title":"J. Clin. Oncol."},{"key":"58183_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann. Oncol. 34, 681\u2013692 (2023).","journal-title":"Ann. Oncol."},{"key":"58183_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"AM Patch","year":"2015","unstructured":"Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489\u2013494 (2015).","journal-title":"Nature"},{"key":"58183_CR6","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/cncr.21767","volume":"106","author":"DG Rosen","year":"2006","unstructured":"Rosen, D. G. et al. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 106, 1925\u20131932 (2006).","journal-title":"Cancer"},{"key":"58183_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/GCO.0000000000000832","volume":"35","author":"CM Eakin","year":"2023","unstructured":"Eakin, C. M., Lai, T. & Cohen, J. G. Alarming trends and disparities in high-risk endometrial cancer. Curr. Opin. Obstet. Gynecol. 35, 15\u201320 (2023).","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"58183_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ccell.2017.02.010","volume":"31","author":"AD Cherniack","year":"2017","unstructured":"Cherniack, A. D. et al. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell 31, 411\u2013423 (2017).","journal-title":"Cancer Cell"},{"key":"58183_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","volume":"22","author":"A da Costa","year":"2023","unstructured":"da Costa, A., Chowdhury, D., Shapiro, G. I., D\u2019Andrea, A. D. & Konstantinopoulos, P. A. Targeting replication stress in cancer therapy. Nat. Rev. Drug Discov. 22, 38\u201358 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"58183_CR10","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1021\/acs.jmedchem.8b01469","volume":"62","author":"S Tadesse","year":"2019","unstructured":"Tadesse, S., Caldon, E. C., Tilley, W. & Wang, S. Cyclin-dependent kinase 2 inhibitors in cancer therapy: An update. J. Med. Chem. 62, 4233\u20134251 (2019).","journal-title":"J. Med. Chem."},{"key":"58183_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100394","volume":"2","author":"H Xu","year":"2021","unstructured":"Xu, H. et al. CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Rep. Med. 2, 100394 (2021).","journal-title":"Cell Rep. Med."},{"key":"58183_CR12","doi-asserted-by":"publisher","first-page":"20801","DOI":"10.18632\/oncotarget.4600","volume":"6","author":"L Yang","year":"2015","unstructured":"Yang, L. et al. Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression. Oncotarget 6, 20801\u201320812 (2015).","journal-title":"Oncotarget"},{"key":"58183_CR13","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-13-2247","volume":"74","author":"AM Karst","year":"2014","unstructured":"Karst, A. M. et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 74, 1141\u20131152 (2014).","journal-title":"Cancer Res."},{"key":"58183_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4161\/cc.11.1.18775","volume":"11","author":"KT Siu","year":"2012","unstructured":"Siu, K. T., Rosner, M. R. & Minella, A. C. An integrated view of cyclin E function and regulation. Cell Cycle 11, 57\u201364 (2012).","journal-title":"Cell Cycle"},{"key":"58183_CR15","doi-asserted-by":"publisher","unstructured":"Matson, J. P. et al. Rapid DNA replication origin licensing protects stem cell pluripotency. Elife 6, https:\/\/doi.org\/10.7554\/eLife.30473 (2017).","DOI":"10.7554\/eLife.30473"},{"key":"58183_CR16","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.cell.2022.12.036","volume":"186","author":"J Zeng","year":"2023","unstructured":"Zeng, J., Hills, S. A., Ozono, E. & Diffley, J. F. X. Cyclin E-induced replicative stress drives p53-dependent whole-genome duplication. Cell 186, 528\u2013542 (2023).","journal-title":"Cell"},{"key":"58183_CR17","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41586-022-04638-9","volume":"604","author":"D Gallo","year":"2022","unstructured":"Gallo, D. et al. CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Nature 604, 749\u2013756 (2022).","journal-title":"Nature"},{"key":"58183_CR18","doi-asserted-by":"publisher","first-page":"22300","DOI":"10.1074\/jbc.272.35.22300","volume":"272","author":"RN Booher","year":"1997","unstructured":"Booher, R. N., Holman, P. S. & Fattaey, A. Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity. J. Biol. Chem. 272, 22300\u201322306 (1997).","journal-title":"J. Biol. Chem."},{"key":"58183_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrfmmm.2020.111694","volume":"819-820","author":"CR Elbaek","year":"2020","unstructured":"Elbaek, C. R., Petrosius, V. & Sorensen, C. S. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry. Mutat. Res. 819-820, 111694 (2020).","journal-title":"Mutat. Res."},{"key":"58183_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0092-8674(93)80048-J","volume":"74","author":"R Heald","year":"1993","unstructured":"Heald, R., McLoughlin, M. & McKeon, F. Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated Cdc2 kinase. Cell 74, 463\u2013474 (1993).","journal-title":"Cell"},{"key":"58183_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1128\/MCB.17.2.571","volume":"17","author":"F Liu","year":"1997","unstructured":"Liu, F., Stanton, J. J., Wu, Z. & Piwnica-Worms, H. The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Mol. Cell Biol. 17, 571\u2013583 (1997).","journal-title":"Mol. Cell Biol."},{"key":"58183_CR22","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1002\/j.1460-2075.1992.tb05493.x","volume":"11","author":"Y Gu","year":"1992","unstructured":"Gu, Y., Rosenblatt, J. & Morgan, D. O. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J. 11, 3995\u20134005 (1992).","journal-title":"EMBO J."},{"key":"58183_CR23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1091\/mbc.5.3.273","volume":"5","author":"S Kornbluth","year":"1994","unstructured":"Kornbluth, S., Sebastian, B., Hunter, T. & Newport, J. Membrane localization of the kinase which phosphorylates p34cdc2 on threonine 14. Mol. Biol. Cell 5, 273\u2013282 (1994).","journal-title":"Mol. Biol. Cell"},{"key":"58183_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-020-00270-2","volume":"9","author":"YP Kok","year":"2020","unstructured":"Kok, Y. P. et al. Overexpression of Cyclin E1 or Cdc25A leads to replication stress, mitotic aberrancies, and increased sensitivity to replication checkpoint inhibitors. Oncogenesis 9, 88 (2020).","journal-title":"Oncogenesis"},{"key":"58183_CR25","doi-asserted-by":"publisher","first-page":"6594","DOI":"10.1158\/1078-0432.CCR-18-1446","volume":"24","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. Cyclin E overexpression sensitizes triple-negative breast cancer to wee1 kinase inhibition. Clin. Cancer Res. 24, 6594\u20136610 (2018).","journal-title":"Clin. Cancer Res."},{"key":"58183_CR26","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrm.2017.67","volume":"18","author":"JC Saldivar","year":"2017","unstructured":"Saldivar, J. C., Cortez, D. & Cimprich, K. A. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat. Rev. Mol. Cell Biol. 18, 622\u2013636 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"58183_CR27","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nsmb.2076","volume":"18","author":"LI Toledo","year":"2011","unstructured":"Toledo, L. I. et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat. Struct. Mol. Biol. 18, 721\u2013727 (2011).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"58183_CR28","doi-asserted-by":"publisher","first-page":"10251","DOI":"10.1021\/acs.jmedchem.2c00552","volume":"65","author":"J Szychowski","year":"2022","unstructured":"Szychowski, J. et al. Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306. J. Med. Chem. 65, 10251\u201310284 (2022).","journal-title":"J. Med. Chem."},{"key":"58183_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","volume":"21","author":"A Roulston","year":"2022","unstructured":"Roulston, A. et al. RP-3500: A novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and in combination with PARP inhibitors. Mol. Cancer Ther. 21, 245\u2013256 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"58183_CR30","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41591-023-02399-0","volume":"29","author":"TA Yap","year":"2023","unstructured":"Yap, T. A. et al. Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat. Med. 29, 1400\u20131411 (2023).","journal-title":"Nat. Med."},{"key":"58183_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111081","volume":"40","author":"M Zimmermann","year":"2022","unstructured":"Zimmermann, M. et al. Guiding ATR and PARP inhibitor combinationswith chemogenomic screens. Cell Rep. 40, 111081 (2022).","journal-title":"Cell Rep."},{"key":"58183_CR32","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","volume":"155","author":"LI Toledo","year":"2013","unstructured":"Toledo, L. I. et al. ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 155, 1088\u20131103 (2013).","journal-title":"Cell"},{"key":"58183_CR33","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.aap9346","volume":"361","author":"JC Saldivar","year":"2018","unstructured":"Saldivar, J. C. et al. An intrinsic S\/G(2) checkpoint enforced by ATR. Science 361, 806\u2013810 (2018).","journal-title":"Science"},{"key":"58183_CR34","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1101\/gad.14.12.1448","volume":"14","author":"Q Liu","year":"2000","unstructured":"Liu, Q. et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)\/M DNA damage checkpoint. Genes Dev. 14, 1448\u20131459 (2000).","journal-title":"Genes Dev."},{"key":"58183_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26811-w","volume":"12","author":"A Datta","year":"2021","unstructured":"Datta, A. et al. WRN helicase safeguards deprotected replication forks in BRCA2-mutated cancer cells. Nat. Commun. 12, 6561 (2021).","journal-title":"Nat. Commun."},{"key":"58183_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.devcel.2010.02.013","volume":"18","author":"O Gavet","year":"2010","unstructured":"Gavet, O. & Pines, J. Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev. Cell 18, 533\u2013543 (2010).","journal-title":"Dev. Cell"},{"key":"58183_CR37","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/ncb918","volume":"5","author":"M Jackman","year":"2003","unstructured":"Jackman, M., Lindon, C., Nigg, E. A. & Pines, J. Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat. Cell Biol. 5, 143\u2013148 (2003).","journal-title":"Nat. Cell Biol."},{"key":"58183_CR38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrc2169","volume":"7","author":"R Boutros","year":"2007","unstructured":"Boutros, R., Lobjois, V. & Ducommun, B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat. Rev. Cancer 7, 495\u2013507 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"58183_CR39","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3892\/ijo.2015.3268","volume":"48","author":"K Nakayama","year":"2016","unstructured":"Nakayama, K. et al. CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas. Int. J. Oncol. 48, 506\u2013516 (2016).","journal-title":"Int. J. Oncol."},{"key":"58183_CR40","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1002\/cncr.30435","volume":"123","author":"SY Lim","year":"2017","unstructured":"Lim, S. Y., Menzies, A. M. & Rizos, H. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma. Cancer 123, 2118\u20132129 (2017).","journal-title":"Cancer"},{"key":"58183_CR41","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1200\/JCO.2011.37.6418","volume":"31","author":"TA Yap","year":"2013","unstructured":"Yap, T. A., Omlin, A. & de Bono, J. S. Development of therapeutic combinations targeting major cancer signaling pathways. J. Clin. Oncol. 31, 1592\u20131605 (2013).","journal-title":"J. Clin. Oncol."},{"key":"58183_CR42","doi-asserted-by":"publisher","first-page":"PR008","DOI":"10.1158\/1535-7163.TARG-23-PR008","volume":"22","author":"TA Yap","year":"2023","unstructured":"Yap, T. A. et al. MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A. Mol. Cancer Ther. 22, PR008 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"58183_CR43","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/1078-0432.CCR-21-0158","volume":"28","author":"KN Moore","year":"2022","unstructured":"Moore, K. N. et al. Adavosertib with chemotherapy in patients with primary platinum-resistant ovarian, fallopian tube, or peritoneal cancer: An open-label, four-arm, phase II study. Clin. Cancer Res. 28, 36\u201344 (2022).","journal-title":"Clin. Cancer Res."},{"key":"58183_CR44","doi-asserted-by":"publisher","first-page":"19489","DOI":"10.1073\/pnas.1314302110","volume":"110","author":"D Etemadmoghadam","year":"2013","unstructured":"Etemadmoghadam, D. et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc. Natl. Acad. Sci. USA 110, 19489\u201319494 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"58183_CR45","doi-asserted-by":"publisher","unstructured":"Chen, X. et al. Targeting replicative stress and DNA repair by combining PARP and wee1 kinase inhibitors is synergistic in triple negative breast cancers with cyclin E or BRCA1 alteration. Cancers 13, https:\/\/doi.org\/10.3390\/cancers13071656 (2021).","DOI":"10.3390\/cancers13071656"},{"key":"58183_CR46","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.1038\/s41388-022-02527-z","volume":"41","author":"M Li","year":"2022","unstructured":"Li, M. et al. Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer. Oncogene 41, 5331\u20135346 (2022).","journal-title":"Oncogene"},{"key":"58183_CR47","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc2290","volume":"8","author":"M Welcker","year":"2008","unstructured":"Welcker, M. & Clurman, B. E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 8, 83\u201393 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"58183_CR48","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062\u2013D1067 (2018).","journal-title":"Nucleic Acids Res."},{"key":"58183_CR49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fonc.2017.00024","volume":"7","author":"T Worzfeld","year":"2017","unstructured":"Worzfeld, T. et al. The unique molecular and cellular microenvironment of ovarian cancer. Front. Oncol. 7, 24 (2017).","journal-title":"Front. Oncol."},{"key":"58183_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.998388","volume":"12","author":"L Carlsen","year":"2022","unstructured":"Carlsen, L. & El-Deiry, W. S. Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation. Front. Oncol. 12, 998388 (2022).","journal-title":"Front. Oncol."},{"key":"58183_CR51","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89760","volume":"2","author":"E George","year":"2017","unstructured":"George, E. et al. A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight 2, e89760 (2017).","journal-title":"JCI Insight"},{"key":"58183_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim, H. et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat. Commun. 11, 3726 (2020).","journal-title":"Nat. Commun."},{"key":"58183_CR53","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","volume":"560","author":"SM Noordermeer","year":"2018","unstructured":"Noordermeer, S. M. et al. The shieldin complex mediates 53BP1-dependent DNA repair. Nature 560, 117\u2013121 (2018).","journal-title":"Nature"},{"key":"58183_CR54","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","volume":"25","author":"O Kopper","year":"2019","unstructured":"Kopper, O. et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat. Med. 25, 838\u2013849 (2019).","journal-title":"Nat. Med."},{"key":"58183_CR55","doi-asserted-by":"publisher","first-page":"e2005970","DOI":"10.1371\/journal.pbio.2005970","volume":"16","author":"C McQuin","year":"2018","unstructured":"McQuin, C. et al. CellProfiler 3.0: Next-generation image processing for biology. PLoS Biol. 16, e2005970 (2018).","journal-title":"PLoS Biol."},{"key":"58183_CR56","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1158\/1078-0432.CCR-16-2273","volume":"23","author":"H Kim","year":"2017","unstructured":"Kim, H. et al. Targeting the ATR\/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models. Clin. Cancer Res. 23, 3097\u20133108 (2017).","journal-title":"Clin. Cancer Res."},{"key":"58183_CR57","doi-asserted-by":"publisher","first-page":"e1462431","DOI":"10.1080\/2162402X.2018.1462431","volume":"7","author":"DP Enot","year":"2018","unstructured":"Enot, D. P., Vacchelli, E., Jacquelot, N., Zitvogel, L. & Kroemer, G. TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves. Oncoimmunology 7, e1462431 (2018).","journal-title":"Oncoimmunology"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58183-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58183-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58183-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T13:43:58Z","timestamp":1743774238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58183-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["58183"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-58183-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3854682\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"7 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F.S. serves on scientific advisory boards for AstraZeneca, GSK, and Zentalis Pharmaceuticals. She has received institutional research funding from AstraZeneca, Repare Therapeutics, Instill Bio, and Sierra Oncology. R.K., J.F., R.S., E.A., S.Y.Y., C.G.M. are, and D.G., M.L.H., A.P., A.S. were employees of Repare Therapeutics. R.A.G. serves on the scientific advisory board for Dong-A ST. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3112"}}